Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma
Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma
Relapsed and Refractory|Lymphoid Hematological Malignancies
DRUG: GC022F CAR-T cells
Dose-limiting toxicity (DLT), Proportion of patients with dose limiting toxicity (DLT) after cell infusion, Within 28 days after cell infusion|Incidence of treatment-emergent adverse events (TEAEs), Incidence of treatment-emergent adverse events \[Safety and Tolerability\], 24 months after cell infusion
Overall response rate(ORR), Assessment of ORR (ORR = CR + CRi ) at Month 1,3,6,12,18and 24, Month 1,3,6,12,18and 24|Progression-free survival (PFS), Assessment of PFS at Month 6,12,18and 24, Month 6,12,18and 24|Overall survival (OS), Assessment of OS at Month 6,12,18and 24, Month 6,12,18and 24|Duration of response(DOR), Assessment of OS at Month 6,12,18and 24, Month 6,12,18and 24
This is a single-arm, single-center, open clinical study to evaluate the safety and efficacy of GC022F injection in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.